Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.

Giachelia M, Voso MT, Tisi MC, Martini M, Bozzoli V, Massini G, D'Aló F, Larocca LM, Leone G, Hohaus S.

Leuk Lymphoma. 2012 Mar;53(3):411-6. doi: 10.3109/10428194.2011.621566. Epub 2011 Oct 24.

PMID:
21902578
2.

Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.

Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI.

Korean J Intern Med. 2014 Nov;29(6):785-92. doi: 10.3904/kjim.2014.29.6.785. Epub 2014 Oct 31.

3.

Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.

Stefancikova L, Moulis M, Fabian P, Vasova I, Zedek F, Ravcukova B, Muzik J, Kuglik P, Vranova V, Falkova I, Hrabalkova R, Smardova J.

Int J Oncol. 2011 Dec;39(6):1413-20. doi: 10.3892/ijo.2011.1170. Epub 2011 Aug 18.

PMID:
21874232
4.

Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas.

Tarabar O, Cikota-Aleksić B, Tukić L, Milanović N, Aleksić A, Magić Z.

Int J Clin Oncol. 2014 Feb;19(1):186-92. doi: 10.1007/s10147-013-0531-z. Epub 2013 Mar 27.

PMID:
23532628
5.

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U.

Lancet Oncol. 2017 Aug;18(8):1076-1088. doi: 10.1016/S1470-2045(17)30444-8. Epub 2017 Jun 28.

PMID:
28668386
6.

Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.

Huang YC, Liu CY, Lu HJ, Liu HT, Hung MH, Hong YC, Hsiao LT, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Tzeng CH, Yu YB.

Ann Hematol. 2013 Nov;92(11):1513-20. doi: 10.1007/s00277-013-1807-0. Epub 2013 Jun 18.

PMID:
23775580
7.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group.

Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

PMID:
21940214
8.

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.

Seo S, Hong JY, Yoon S, Yoo C, Park JH, Lee JB, Park CS, Huh J, Lee Y, Kim KW, Ryu JS, Kim SJ, Kim WS, Yoon DH, Suh C.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.

9.

MYC protein expression is associated with poor prognosis in diffuse large B cell lymphoma patients treated with RCHOP chemotherapy.

Zhou M, Wang J, Ouyang J, Xu JY, Chen B, Zhang QG, Zhou RF, Yang YG, Shao XY, Xu Y, Chen YM, Fan XS, Wu HY.

Tumour Biol. 2014 Jul;35(7):6757-62. doi: 10.1007/s13277-014-1907-z. Epub 2014 Apr 11.

PMID:
24719189
10.

ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.

Kim IS, Kim HG, Kim DC, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Lee GW.

Cancer Sci. 2008 Dec;99(12):2496-501. doi: 10.1111/j.1349-7006.2008.00985.x. Epub 2008 Nov 20.

11.

Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP.

Huang X, Meng B, Iqbal J, Ding BB, Perry AM, Cao W, Smith LM, Bi C, Jiang C, Greiner TC, Weisenburger DD, Rimsza L, Rosenwald A, Ott G, Delabie J, Campo E, Braziel RM, Gascoyne RD, Cook JR, Tubbs RR, Jaffe ES, Armitage JO, Vose JM, Staudt LM, McKeithan TW, Chan WC, Ye BH, Fu K.

J Clin Oncol. 2013 Dec 20;31(36):4520-8. doi: 10.1200/JCO.2012.45.6004. Epub 2013 Nov 12.

12.

Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.

Zaky AH, Bakry R, El-sayed MI, Elwanis MA, Nabih O.

Hematology. 2014 Oct;19(7):412-6. doi: 10.1179/1607845413Y.0000000147. Epub 2014 Jan 20.

PMID:
24620947
13.

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Slack GW, Gascoyne RD, Tu M, Variakojis D, Chen W, Go RS, Piris MA, Møller MB, Medeiros LJ, Young KH.

Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28.

14.

Hyperfibrinogenemia is a poor prognostic factor in diffuse large B cell lymphoma.

Niu JY, Tian T, Zhu HY, Liang JH, Wu W, Cao L, Lu RN, Wang L, Li JY, Xu W.

Ann Hematol. 2018 Oct;97(10):1841-1849. doi: 10.1007/s00277-018-3382-x. Epub 2018 Jun 2.

PMID:
29860562
15.

The highest prognostic impact of LDH among International Prognostic Indices (IPIs): an explorative study of five IPI factors among patients with DLBCL in the era of rituximab.

Park JH, Yoon DH, Kim DY, Kim S, Seo S, Jeong Y, Lee SW, Park CS, Huh J, Suh C.

Ann Hematol. 2014 Oct;93(10):1755-64. doi: 10.1007/s00277-014-2115-z. Epub 2014 Jul 16.

PMID:
25027115
16.

Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2013 Oct;54(10):2205-14. doi: 10.3109/10428194.2013.774392. Epub 2013 Apr 2.

PMID:
23391141
17.

CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ.

J Clin Oncol. 2016 Sep 10;34(26):3150-6. doi: 10.1200/JCO.2015.65.6520. Epub 2016 Jul 5.

PMID:
27382100
18.

Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab.

Chaiwatanatorn K, Stamaratis G, Opeskin K, Firkin F, Nandurkar H.

Leuk Lymphoma. 2009 Oct;50(10):1666-75. doi: 10.1080/10428190903165233.

PMID:
19757311
19.

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C.

Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30.

20.

Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Cho MC, Chung Y, Jang S, Park CJ, Chi HS, Huh J, Suh C, Shim H.

Medicine (Baltimore). 2018 Nov;97(45):e13046. doi: 10.1097/MD.0000000000013046.

Supplemental Content

Support Center